EP2545920A1 — Therapy for complications of diabetes
Assigned to AbbVie Deutschland GmbH and Co KG · Expires 2013-01-16 · 13y expired
What this patent protects
A selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy is disclosed, in particular wherein the selective ET A receptor antagonist comprises at least one agent selected fro…
USPTO Abstract
A selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy is disclosed, in particular wherein the selective ET A receptor antagonist comprises at least one agent selected from the group consisting of atrasentan, ambrisentan, avosentan, BMS 193884, BQ-123, CI-1020, clazosentan, darusentan, edonentan, S-0139, sitaxsentan, TA-0201, TBC 3711, YM-598, ZD-1611, ZD-4054, and salts thereof. Further, such selective ET A receptor antagonist is disclosed in combination with one or more antihypertensives other than selective ET A receptor antagonists for use in said method. Still further, such selective ET A receptor antagonist is disclosed in combination with one or more antidiabetics other than selective ET A receptor antagonists for use in said method.
Drugs covered by this patent
- Tryvio (APROCITENTAN) · Idorsia
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.